IRIS
SANTONI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.365
AS - Asia 3.846
EU - Europa 3.829
SA - Sud America 812
AF - Africa 261
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 5
Totale 19.127
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.198
SG - Singapore 1.331
RU - Federazione Russa 722
VN - Vietnam 708
BR - Brasile 650
CN - Cina 650
IT - Italia 572
UA - Ucraina 476
SE - Svezia 392
IE - Irlanda 389
DE - Germania 370
HK - Hong Kong 363
FR - Francia 207
TR - Turchia 203
FI - Finlandia 188
GB - Regno Unito 168
DK - Danimarca 158
CI - Costa d'Avorio 151
IN - India 140
KR - Corea 104
CA - Canada 102
BD - Bangladesh 89
AR - Argentina 61
NL - Olanda 43
JP - Giappone 42
ID - Indonesia 39
MX - Messico 37
PL - Polonia 36
ZA - Sudafrica 36
IQ - Iraq 30
CO - Colombia 25
MA - Marocco 24
EE - Estonia 23
EC - Ecuador 22
PK - Pakistan 22
BE - Belgio 19
PH - Filippine 19
ES - Italia 18
VE - Venezuela 15
UZ - Uzbekistan 13
EG - Egitto 10
PY - Paraguay 10
SA - Arabia Saudita 10
TN - Tunisia 10
MY - Malesia 9
AT - Austria 8
AZ - Azerbaigian 8
CL - Cile 8
DZ - Algeria 8
IL - Israele 8
LB - Libano 8
PE - Perù 8
AU - Australia 7
BO - Bolivia 7
CZ - Repubblica Ceca 7
KE - Kenya 7
KZ - Kazakistan 7
DO - Repubblica Dominicana 6
PS - Palestinian Territory 6
TT - Trinidad e Tobago 6
EU - Europa 5
JO - Giordania 5
NP - Nepal 5
AL - Albania 4
BY - Bielorussia 4
CH - Svizzera 4
LT - Lituania 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
ET - Etiopia 3
GR - Grecia 3
TH - Thailandia 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
HN - Honduras 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
LU - Lussemburgo 2
MU - Mauritius 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
RS - Serbia 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CY - Cipro 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
IM - Isola di Man 1
Totale 19.109
Salva come PNG Salva come JPEG
Città #
Ashburn 1.695
Singapore 888
Chandler 857
Fairfield 705
Des Moines 687
Dallas 545
Jacksonville 529
San Jose 429
Dublin 387
Wilmington 381
Hong Kong 358
Boardman 317
Woodbridge 306
Seattle 274
Houston 259
New York 256
Ho Chi Minh City 228
The Dalles 197
Cambridge 195
Beijing 161
Hanoi 160
Lawrence 159
Princeton 159
San Mateo 153
Abidjan 151
Lauterbourg 140
Los Angeles 140
Ann Arbor 126
Moscow 113
Centro 98
Munich 89
San Diego 79
Council Bluffs 67
Helsinki 65
Milan 62
Pune 59
Hefei 54
São Paulo 49
Columbus 47
Da Nang 47
Orem 47
Vancouver 45
London 43
Turku 43
Chicago 40
Washington 40
Santa Clara 38
Turin 38
Tokyo 37
Buffalo 36
Marche 33
Haiphong 31
Warsaw 31
Brooklyn 28
Frankfurt am Main 28
Guangzhou 27
Redmond 26
Miano 24
Atlanta 22
Chennai 22
Falls Church 22
Montreal 22
Shanghai 22
Denver 21
Ancona 20
Norwalk 20
Johannesburg 19
Mexico City 19
San Francisco 19
Wuhan 19
Brussels 17
Rio de Janeiro 17
Belo Horizonte 16
Manchester 16
Phoenix 16
Brasília 15
Poplar 15
Rome 15
Stockholm 15
Jakarta 14
Jiaxing 14
Hải Dương 13
Tashkent 13
Amsterdam 12
Baghdad 12
Can Tho 12
Porto Alegre 12
Seoul 12
Ankara 11
Kilburn 11
Mumbai 11
Guarulhos 10
New Delhi 10
Quận Ba 10
Thái Nguyên 10
Boston 9
Curitiba 9
Dhaka 9
Elk Grove Village 9
Fayetteville 9
Totale 12.927
Salva come PNG Salva come JPEG
Nome #
Metabolic phenotype of bladder cancer 260
Designing novel immunocombinations in metastatic renal cell carcinoma 201
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 198
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 198
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 194
Predicting future cancer burden in the United States by artificial neural networks 190
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 189
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 183
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 181
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 178
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 176
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 173
Exploring the Spectrum of Kidney Ciliopathies 167
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 165
HER family receptor expression and prognosis in pancreatic cancer 165
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 165
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 165
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date 164
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 161
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 161
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 161
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 160
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 160
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 160
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 159
An update on investigational therapies that target STAT3 for the treatment of cancer 158
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 156
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 156
Microbiome and cancers, with focus on genitourinary tumors 155
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 153
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 153
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 152
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 152
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 152
Metabolic Alterations in Renal and Prostate Cancer 151
High CTLA-4 expression correlates with poor prognosis in thymoma patients 149
Molecular characterization of testicular germ cell tumors using tissue microdissection 147
Bone targeting agents in patients with metastatic prostate cancer: State of the art 147
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 146
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 145
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 143
Is There a Role for Immunotherapy in Prostate Cancer? 143
Trattamento del carcinoma del pancreas. Attualità e prospettive 141
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 141
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 141
Hyponatremia in cancer patients: Time for a new approach 140
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 138
Pd-l1 inhibitors for the treatment of prostate cancer 136
AR-V7 and prostate cancer: The watershed for treatment selection? 135
IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME 134
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 134
Bladder cancer: molecular determinants of personalized therapy 133
An overview of emerging immunotargets of genitourinary tumors 132
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 132
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 132
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 132
Present and future of personalized medicine in adult genitourinary tumors 131
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 130
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 129
The identification of immunological biomarkers in kidney cancers 128
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 127
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 127
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 126
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 125
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 124
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 124
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 124
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 124
An update on immunotherapy in uro-oncology 123
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 121
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 120
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 119
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 119
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 118
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 118
Urinary catheters and biofilm formation 117
Emerging Immunotargets and Immunotherapies in Prostate Cancer 117
Renal Cell Carcinoma: genomic landscape and clinical implications 117
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 116
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 114
Role of STAT3 pathway in genitourinary tumors 113
Treating prostate cancer by antibody-drug conjugates 113
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 112
Epigenetic modulations and lineage plasticity in advanced prostate cancer 112
Agent-Based Learning Model for the Obesity Paradox in RCC 112
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 111
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 111
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 111
Exploring small extracellular vesicles for precision medicine in prostate cancer 110
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 110
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 110
The route to personalized medicine in bladder cancer: where do we stand? 110
Pazopanib and sunitinib trigger autophagic and non autophagic death of bladder tumor cells. 109
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 109
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 109
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 109
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 108
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 107
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 107
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 107
Totale 14.031
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202170 0 0 0 0 0 0 0 0 0 0 0 70
2021/20221.346 200 208 40 24 26 142 33 65 101 118 134 255
2022/20232.865 238 271 148 214 151 879 6 156 584 13 152 53
2023/20241.401 238 34 99 162 203 362 30 41 4 30 17 181
2024/20252.547 322 206 32 16 103 88 240 92 585 239 275 349
2025/20267.073 447 509 475 541 824 466 1.335 735 662 569 160 350
Totale 19.389